Clinical Trials for Cancer Type: Brain and Nervous System

19 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ALLIANCE-A071401 Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations Open
ALLIANCE-A221101 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma Open
ECOG-EAF151 (CIRB) Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent Glioblastoma Open
ECOG-EAY131 (CIRB) Molecular Analysis for Therapy Choice (MATCH) Open
NRG-BN001 (CIRB) Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Open
NRG-BN003 (CIRB) Phase III trial of observation versus irradiation for a gross totally resected grade II meningioma Open
RTOG-3503 Phase II Trial of Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma Open
SWOG-S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-12-18 (BIOREPOSITORY PROTOCOL) Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments Open
UCI-13-14 A Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671/ GM-CSF / Cyclophosphamide) + Bevacizumab vs. (Placebo Injection / Placebo pill) + Bevacizumab in the treatment of recurrent/progressive, Bevacizumab naïve glioblastoma multiforme and gliosarcoma patients (WHO grade IV malignant gliomas) Open
UCI-15-35 A Phase 2/3 Randomized, Open Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma Open
UCI-15-79 Phase II Open-Label Randomized Study of Radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) Open
UCI-15-99 Open-label, non-randomized, phase 2 study evaluating efficacy and safety of PQR309 in patients with relapsed or refractory primary CNS lymphoma Open
UCI-16-54 Identification of functional MRI, neuropsychiatric, and circulating VEGF changes after marizomib treatment in patients enrolled in the UCI 14-58 study (single agent marizomib cohort) Open
UCI-16-55 Phase 1b, Multicenter, Open-Label Study of Marizomib with Temozolomide and Radiotherapy in Patients with Newly Diagnosed WHO Grade IV Malignant Glioma Open
UCI-16-74 A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine Open
UCI-16-96 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Open
UCI-17-13 Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice Open
UCI-17-91 [EXEMPTED] Compassionate Use study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemotherapy Open